MedTrace Logo

PCSK9 Inhibitors in the Progression of Aortic Stenosis

NCT03051360 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2017-02-13

No results posted yet for this study

Summary

Investigators plan evaluate whether PCSK9 inhibitors, a medication that can lower lipoprotein(a) and control dyslipidemia, can inhibit the progression of aortic stenosis, through a randomized controlled trial.

Conditions

  • Aortic Valve Stenosis

Interventions

DRUG

PCSK9 Inhibitor [EPC]

Patients will receive PCSK9 inhibitor by a biweekly injection

DRUG

Placebos

Patients will receive Placebo by a biweekly injection

Sponsors & Collaborators

  • Seoul National University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-01
Primary Completion
2019-12-31
Completion
2020-01-01
FDA Drug
Yes

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03051360 on ClinicalTrials.gov